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The pharmaceutical industry is among high technology industries that needs considerable attention in 
research and development. Overall, the processes that a drug must go through from its production in 
the laboratory, to clinical trials on certain groups, to the drug being licensed and finally planning for its 
marketing makes it different to any other product. Boosting research and development capability in this 
industry as well as saving patients’ lives is also essential in controlling the costs of importing drugs. 
According to this point of view, having suitable R and D strategies in the pharmaceutical sector 
becomes very important for every country. In this study, we aimed to review several studies concerning 
biological drugs R and D in selected countries. Since the discussions in relation to the R and D within 
the pharmaceutical sector about biological drugs come under the umbrella of innovation system of 
each country. By reviewing the pharmaceutical innovation system studies of selected OECD countries 
including Norway, Germany and Japan, we aimed to look at the main factors in national R and D 
system, the trading system conditions, R and D co-operations, human resources, financial matters, 
entrepreneurship, the market, R and D policy making and coordination of different organizations and 
main support policies within the biological drugs system. 
 





During the recent years, developing countries such as 
Iran have not achieved noticeable success in the modern 
biotechnology field (Soleimani, 1997). This observation 
applies to different pharmaceutical sectors not just the 
biological drug sector. These products have a direct 
relationship to public health and are important within 
society (Hamzeh-Pour, 1997). Access to new drugs is an 
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out trials (Gale and Clark, 2000). According to statistics, 
one of the main barriers to success in the biological drugs 
industry is lack of systematic attention to R and D in this 
sector (Behboodi, 1997). It is not that difficult to hold a 
systemic view in the pharmaceutical industry (McKelvey 
and Orsenigo, 2001). In this point of view, attention is 
paid to different elements and their relationship to each 
other (Nejad and Sasan-gohar, 2002). Among countries 
that have carried out reliable studies in this field are 
members of the OECD (Noori-Hekmat, 2009). The main 
aim of these studies was to review the innovation system 
of biological drugs in these countries. The R and D 
discussion was also included in the  report  (Esmailzadeh  




and Dehnavieh, 2004). Japan, Germany and Norway 
were chosen as a sample and the main factors affecting 
the R and D of biological drugs were reviewed. A review 
of these countries’ experiences has important lessons  for 
developing countries such as Iran. References have been 
made to these experiences.  
 
 
MATERIALS AND METHODS  
 
The method of this study (carried out in 2010) was cross-sectional 
and comparative study. The research society consisted of all OECD 
countries and 3 countries were selected as study sample. This 
study was conducted in three stages. Research literature in the first 
stage was investigated. In the next stage, the biotechnology 
research and development (R and D) situation concerning 
biological drugs was reviewed in Japan, Germany and Norway. 
Data collection was done through documents reviewing. Finally, 
tried to providing useful strategies for other countries, especially 
developing countries in this area. 
 
 




R and D system   
 
Universities, public research centres and private research 
centres form important elements of the biological drugs R 
and D system in Japan. The most important organization 
in the field of biological drugs in Japan is the national 
cancer research centre which is supervised by the 
Ministry of Health, Work and Welfare. The Agency for 
Industrial Science and Technology (AISI) is part of the 
economics, trade and industry ministry and plays an 
important role in biotechnology research. The physical 
and chemical research institute and university hospitals 
such as Tokyo University Hospital carry out considerable 





In 2003, there were 334 biotechnology companies in 
Japan. In recent years, the number of these companies 
has grown rapidly. However, in comparison to 2000 
companies in the US and 2500 in Europe, Japan has few 
biotechnology companies. The relative size of these 





Billions of yens are assigned to new drugs R and D and it 
takes more than ten years to develop and produce. Since 
the drugs industry needs intensive R and D and the 
relative R and D costs to production and sales are high; 
cooperation with international organizations is vital for 







The number of qualifications relevant to biotechnology  in 





The cost of biotechnology R and D within public research 
centres and universities is almost entirely met by the 
government, more than half of all biotechnology costs is 
also paid by the government. The costs of biotechnology 
R and D is always increasing and is rising faster than 
other R and D. In order to boost the market, it is 
necessary to encourage industry to support joint 






In recent years, the number of biotechnology companies 
has increased. In the past 2 to 3 years, approximately 50 





An increase in pharmaceutical product imports and parti-
cipation of foreign companies in the Japanese market 
has made a competitive environment even more 
competitive. Despite Japan’s gradual shrinking in the 
world market, it has managed to keep a sizeable portion 
of the world market (15%) and it is still an attractive 
market for international corporations. The most influential 
factors in Japan’s pharmaceutical industry include: 
Reforms in the pharmaceutical management system and 
a review of government regulatory supervision in clinical 
trials and new drugs. New drugs pricing is based on the 
price of a similar product, plus a certain percentage 
depending on innovation, the drug’s effectiveness and 
market tolerance. In 2003, the fix price regulation came 
into force to control prices (only exclusive, non-generic 
drugs that made major improvement to patients were 
exempt from the requirements). 
Japanese pharmaceutical companies have slowly 
formed R and D partnerships with international com-
panies and have achieved good results (biological drugs). 
Japanese pharmaceutical companies have realized that 
in order to make progress in many fields, they cannot just 
rely on their own human resources and technology. 
Therefore, they supported joint co-operations. Opinion 
poll showed pharmaceutical companies favour supporting 
co-operations with other companies, especially Japanese 
universities as well as public research organizations and 
international investment companies. On the other hand, 
further studies into these co-operations made it clear that 





national research organizations was to obtain public 
knowledge and meanwhile, development of new drugs 
was reliant on international investment. 
 
 
R and D policy making 
 
In Japan, different organizations are involved in 
biotechnology R and D and biotechnology innovation. 
The most important are: Ministry of Health, Work and 
Welfare (medical), The Ministry of Economy Trade and 
Industry (industrial goods) and the Ministry of Agriculture 
Forestry and Fishing (agricultural products). In addition, 
the Ministry of Education Culture, Sport and Science and 
Technology is responsible for higher education and public 
research organizations. These four ministries work toge-
ther and are responsible for Japan’s policy making. 
Recently, the prime minister’s cabinet office set up the 
Biotechnology Strategy Council (BTSC) to further 
develop biotechnology in Japan. BTSC is responsible for 
coordinating policy making in different departments. 
BTSC’s biotechnology strategy instructions include three 
vital strategies to make technology accessible and 
available, to strengthen the industrial process and 
understanding the public needs. The Council for Science 
and Technology Policy (CSTP) based on prime minister’s 
office coordinates various ministries’ technology policies. 
CSTP’s main responsibility is to publish the science and 
technology plan every five years to clarify government’s 
future science and technology policy. Recently, 
government corporations have undertaken the following 
policies to further develop biotechnology. 
 
Policies: Base science support policies: One of the 
key policies for expansion of base sciences in 
biotechnology is to increase biotechnology R and D 
budget. Besides, budgets that have been allocated to 
public projects researchers in universities or public 
research organizations can access budgets that have 
been dedicated to increase competitiveness.       
Another helpful measure adopted is the favourable 
change in the R and D taxation system. R and D tax 
credit system was reviewed recently that resulted in 
further tax incentives. In the new system, a tax incentive 
for investment in pharmaceutical R and D was increased. 
This law can have a major influence on large 
pharmaceutical companies’ R&D. 
 
 
Policies in support of commercialization 
 
As far as universities are concerned, the technology 
transfer (development law) from universities to industry 
plays an important role in commercialization. In 1998, this  
law was passed to enable technology licensing offices 
(TLOs) to support public research institutes. 
During the 1987 financial year, joint research centres 
were set up in universities to promote industrial co-opera- 




tion. These centres create an environment to carry out 
joint research between universities and private cor-
porations. These organizations are used as places by 
industry and university representatives to interact. 
Existence  of   a   suitable  system  to  protect  intellectual 
property rights motivates researchers to commercialize 
their research results. To protect intellectual property 
rights concerning university internal research, the Ministry 
of Science and Technology has established regulations in 





R and D system 
 
The main factor in the German pharmaceutical R and D 
industry is the universities. As well as universities, public 
sector research organizations (POROs) are also active in 
biological drugs field. 
Alongside these key factors, some federal ministries’ 
research organizations departments are active in this 
system. For example, the German federation of industrial 
research association can be referred to. The European 
molecular biology laboratory (EMBL) not only carries out 
basic bio-molecular research, but also transfers research 
results to industrial applications. In addition, the EMBL 
runs educational courses in molecular biology.  
 
 
Trading system  
 
Key organizations in the pharmaceutical industry include 
active biotechnology pharmaceutical companies, spe-
cialized biotechnology companies, supplier companies 
and clinical research organizations. The mergers and 
company purchases is among the interesting facts that 
can be referred to. In the majority of these cases, one of 
the partners has been an international corporation. This 
proves that the security of the world markets can be a 
major incentive to join them. 
 
 
R and D co-operation 
 
Internally, German pharmaceutical companies co-operate 
with the PSROs. The main aim of this co-operation is to 
gain base knowledge. In relation to international co-
operation, international collaborators tend to co-operate 
with American companies. This shows that German com-
panies find US companies’ attractive partners to co-
operate with. The most important achievements of these 
co-operations are to develop products and marketing, 
and to get  assistance  in  product  distribution.  Repeated 
co-operations take the form of research projects con-
tractual research. In some cases, exchange of 
employees takes place. 






Except in certain specific areas such as clinical medical 
research on patients, currently there are no  shortages  in 
the German biological drugs sector. Nevertheless, the 
approval of the development plan for future university 
graduates shows that planners are concerned about 
human resources in engineering and biological sciences. 
 
 
Financial matters (considerations)  
 
On the whole, there has been stability in investments in 
biotechnology in comparison with other sectors. Offering 
shares is an important strategy for investment 





Although, in the past ten years, entrepreneurship in 
Germany has had good growth and the lack of entre-
preneurship cannot be an important barrier in innovation 
in the biological drugs sector, the promotion of necessary 






Briefly, statistics show there is a strong trend towards the 
American market and an improvement in the position of 
US corporations in the German market. German pharma-
ceutical companies are under competitive pressure in 
world markets as well as in the German market. Despite 
the fact that the growth in German pharmaceutical market 
has been significantly less than the US or other markets, 
Germany is still an attractive market for innovative drugs 
in general and biological drugs in particular. 
 
 
R and D policy making 
 
The German innovative policy system is relatively 
complicated and includes a large number of factors 
(organizations) and ministries involved in federal and 
state level. In addition, different tools have been used to 
support innovation in biotechnology. 
The main quality of the German R and D system is the 
division of political responsibility between the federal 
government and the states (Lander). State (Lander) is 
generally responsible for education. As a result, the state 
provides the majority of university budgets. In addition, 
the state supports research organizations in the state. 
Some states have started special programmes for 
biotechnology that provide the capital for industry and 
research organizations. Federal ministries that are 





several research units that receive the main organi-
zational supports to carry out research activity to satisfy 
the respective needs of their ministry and to discharge 
their political duties. 
Between investment organizations and organizations 
carrying out research, there are intermediary organi-
zations known as project management organizations 
(PMO). The duty of these units include: supporting 
development related to the federal government, analysis 
and evaluation of research projects, to offer consultation 
to investment applicants, evaluation of proposals, 
executive and financial management of current projects 




Policies: Knowledge base support policies: In 
Germany, biotechnology and pharmaceutical knowledge 
base is supported horizontally and vertically. Political 
tools (horizontal support) play the key role in supporting 
biotechnology base sciences. Through this kind of 
investment, research organizations can protect their 
independence and plan and carry out their research 
projects without worrying about political trends or 
ministries’ priorities. 
In relation to vertical policies, during the implementation 
of 4 structural plans major investment in important fields 
such as tissue engineering and genomic micro-organism 
research were undertaken. The groups that benefited 
from these investments were mainly universities, PSROs 
and industry. These activities particularly emphasised 
joint research between universities, PSROs and industry. 
 
 
Policies in support of commercialization 
 
Supporting technological commercialization and industrial 
research investment is the responsibility of the ministry of 
economy. Dedicated support for biotechnology commer-
cialization follows two major approaches. The first 
approach has been attempted to use mechanisms to 
promote biotechnology within the industrial sector. In 
other words, industrial partners have been encouraged to 
cooperate with public research organizations in carrying 
out biotechnology research.  
In the second approach, support programmes for 
biotechnology commercialization have included plans to 
form research units and industrial partnership groups. 
Accordingly, policymakers have tried to transfer biotech-
nology knowledge and its conversion to products, 
processes and services by supporting competition in 
regional research units, investment institutions and 





R and D system 
 





system in Norway is the high percentage of government 
investment. Universities play a minor role in  R  and  D  in 
Norway, it is only 15%. Public and partially public 
institutions are among other organizations active in the 
national R&D system. These institutions are categorized 
according to their research area such as genome, 
nutritional research, marine research and other subjects. 
Among the most important aspects of the Norwegian 




Trading system   
 
While the attention of world pharmaceutical companies is 
focused on therapeutic treatments, many Norwegian 
companies are paying attention to marine biotechnology 
and medical diagnoses. These companies have two main 
reasons for this. Firstly, the development of human 
medical sciences needs larger human resources and 
takes longer in comparison with the development of 
diagnostic tools. Therefore, it is more profitable and less 
risky for Norwegian companies to invest in the dia-
gnostics market. Secondly, these companies can resolve 
difficulties/challenges in their chosen fields without the 
involvement of human bodies. 
On average, specialized biotechnology companies in 
Norway have just over ten employees. A recent opinion 
poll indicates that a large number of Norwegian pharma-
ceutical companies have stated that in the next three 
years cooperating with foreign biotechnology companies 
or university researchers is one of their priorities.  
 
 
R and D cooperation 
 
Norwegian pharmaceutical companies (80%) are more in 
favour of joint cooperation with universities and other 
higher institutions. Depending on the research, R and D 
cooperation in the Norwegian pharmaceutical industry 
varies. Most of it relates to joint R and D (30%), 26% 
relates to R and D contracts, 23% relates to licensing and 
R and D purchases from foreign companies, joint 





It seems access to specialist human resources has been 
a major stumbling block to the Norwegian pharmaceutical 
industry’s progress. It has been one of the main barriers 
to growth in the industry in Norway. Smaller biotech-
nology companies experience more difficulties in 
employing staff than larger pharmaceutical companies.  
 
 
Financial matters (considerations) 
 
The  main  investment  organizations  in  biological  drugs  




research in Norway  are  the  Ministry  Of  Education  and 
Research, the Health Ministry, the Environment Ministry 
and the Ministry Of Trade and Industry. The ministries of 
agriculture and fisheries also play a role in this area. 
Research Council of Norway (RCN) funds most of the 
investment in basic research in Norway. The investment 
is allocated by RCN between different organizations and 
universities. The two main strategies relating to R and D 






The specialised biological drugs companies’ speedy 
growth in Norway shows that entrepreneurship is 
booming in this industry. Nevertheless, entrepreneurship 
has not found its rightful place. One way to resolve this 





Growth in demand for healthcare can play an important 
role in the development of the pharmaceutical industry. 
The pharmaceutical industry is constantly seeking new 
drugs. This trend is more obvious in the Norwegian drugs 
industry as in 2002 more than 37% of products sold in 
Norway were new products. 
In Norway, hospitals are owned by the government, 
investment is also government’s responsibility. In 2002, 
these hospitals became semi-independent. This meant 
that the government became more sensitive to the 
development, production, marketing and sales of 
pharmaceutical products. One of the most important 
factors under supervision was the price of drugs. To 
combat monopolization and reduce healthcare costs, the 
Norwegian drugs agency determines the price of 
prescription drugs based on prices in Austria, Belgium, 
Denmark, Finland, Germany, Ireland and some other 
countries. From the beginning of 2001, the price of 
prescription drugs must not exceed the average price in 
three countries with the lowest prices. 
 
 
R and D policymaking  
 
Other than the Ministry of Education and Research and 
the Trade and Industry Ministry, the Research Council of 
Norway (RCN) and the Norwegian Industrial and 
Regional Development Fund are two other key govern-
ment R and D policymaking organizations. RCN plays the 
most important role in determining research policies in 
Norway. This organization is sponsored by the Ministry of 
Education and Research and is the government’s main 
policy advisor and according to instructions received, 
determines research budgets. RCN as well as being 
responsible  for   investment   management   is   also  the  




government’s advisor in research policies.  
NIRDF provides the specialists and the investment for 
companies in the initial development stages and deve-
lops new and innovative business by finding, improving 
and investing and following up interesting projects. 
NIRDF is decentralized and has 17 regional offices in 
different states. The head office is based in Oslo and has 
management responsibility and is in charge of the NIRDF 
system. As well as the organizations mentioned earlier, 
there are other institutions that act as advisors in 
policymaking to the government. 
 
Policies: Policies for supporting base sciences: To 
support biotechnology knowledge bases as well as 
investment by RCN in research programmes, the 
Norwegian government has chosen the functional 
genome, the Prosbio research programme and a 
programme to establish a molecular biology and 
neurology quality control centre to support. 
 
Policies to support commercialization: To achieve 
commercialization in Norway, a wide range of policies are 
in place for supporting newly established companies to 
issuing invention licence rights in universities. START 
agency for investment is among organizations that are 
active in this field. START is a private investment 
company and was established in 1998. START invests in 
companies that are in their initial stages of their activity 
and have extensive potential for growth and expansion at 
the global level. Among other developments related to 
this category we can point to the increasing trend towards 






Although, the biological drugs industry in developing 
countries is less experienced and operate under different 
conditions than OECD countries, paying attention to R 
and D which is the most important factor in this field can 
be helpful. On the whole, before undertaking biological 
drugs R and D system studies; different parts of the R 
and D system must be identified and their roles clarified. 
The most influential elements in selected countries are 
government organizations and institutions. 
Specialist human resources play a very important role 
biological drugs R and D activities. In most OECD coun-
tries, there is a shortage that needs suitable solutions. 
Due to brain drain in the developing countries, the 
problem is more severe (Noori Hekmat 2009). 
In selected OECD countries, biotechnology R and D 
policy is made at the highest levels of national policy 
making. At this level, responsibility for different policies 
from macro policies, to supporting the biological drugs 
industry, to consultation, to investment, to international 






In the biological drugs industry, the majority of R and D 
costs are met by the government in selected countries. In 
recent years with R and D costs rising, there has been a 
tendency towards joint investments and share offering. It 
is important not to forget that allocation of resources to R 
and D needs planning and this task should be up to 
specialised organizations. 
In selected countries, adequate attention has been paid 
to entrepreneurial factor within the biological drugs 
industry. Despite this, at some levels and especially in 
the contents of university courses, further attention is 
needed. 
Within the biological drugs market, it must be acknow-
ledged that its most important property is the existence of 
strong competition. For governments, one of most 
important concerns in this competitive market is the price 
of drugs; in fact, all countries under review have clear 
and well defined instructions. An important point in the 
biological drugs market is its attractiveness for the 
commercial sector which means increasing number of 
companies is entering this industrial sector. 
The essential point that must always be considered is 
the attention to commercialization. In selected countries, 
among the most important steps to support commercial-
lisation is the establishment of joint university/industry 
research centres within universities. Legislations to 
enhance technology transfer from universities to industry, 
support for newly established companies, attention to 
intellectual property rights and the establishment of 
privately funded incubators are among solutions that can 
be pointed to (Esmail-Zadeh, 2003). In order to protect 
and develop researches related to base knowledge/ 
sciences, different solutions are in practice in selected 
countries. Among these solutions, an increase in budget 
for government research centres, increased investment in 
the field, dedicated budgets to increase competition in the 
field and the creation of motivation in the taxation system 
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